GlassScriptPhysician profile
Ahmed Hussein
NPI 1801000476
$12,479.34
in general payments reported to CMS, 2019-2025
19 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,406 · 2020: $24.22 · 2021: $817 · 2022: $460 · 2023: $292 · 2024: $5,115 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,442 · Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,442.17 |
| Food and Beverage | $2,329.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,152.19 | 2019-2025 | Aveir, Na, Ensite |
| Medtronic Vascular, INC. | $2,823.74 | 2019 | |
| Boston Scientific Corporation | $1,375.63 | 2019-2025 | S-Icd System Magnet, Watchman Flx |
| Medtronic, INC. | $916.54 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Cobalt Dr Mri Surescan |
| Biosense Webster, INC. | $835.23 | 2019-2025 | Carto 3 |
| Novartis Pharmaceuticals Corporation | $305.02 | 2023-2025 | |
| Edwards Lifesciences Corporation | $245.18 | 2025 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $172.19 | 2022 | |
| Abiomed | $155.29 | 2025 | |
| Cardiac Dimensions, INC. | $115.00 | 2025 | |
| Kite Pharma, INC. | $112.87 | 2024 | Yescarta |
| Merck Sharp & Dohme LLC | $80.84 | 2025 | Verquvo, Capvaxive |
| Impulse Dynamics (USA) INC. | $40.56 | 2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $37.71 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $37.19 | 2025 | Uptravi, Opsumit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $21.84 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.68 | 2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2025 | Jardiance |
| Cardiva Medical, INC. | $15.86 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Hussein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.